drugset / Trial / NCT05058352
A Study of HS269 in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I, open-label, first in human study of HS269 tablet, a small molecule highly-selective RET Inhibitor. The dose-escalation study will assess the safety, tolerability, and pharmacokinetics of HS269 and determine the dose and schedule to be used in Phase II. Seventeen to thirty-six patients with advanced solid tumor may be enrolled in this study.
Timeline
- Start
- 2021-10
- Primary completion
- 2022-10
- Completion
- 2023-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS269 | Small molecule | 50 mg | Oral |
| Subject | HS269 | Small molecule | 100 mg | Oral |
| Subject | HS269 | Small molecule | 200 mg | Oral |
| Subject | HS269 | Small molecule | 300 mg | Oral |
| Subject | HS269 | Small molecule | 400 mg | Oral |
| Subject | HS269 | Small molecule | 500 mg | Oral |